Provided by Tiger Fintech (Singapore) Pte. Ltd.

Plus Therapeutics, Inc.

1.57
+0.13009.03%
Pre-market: 1.41-0.1600-10.19%08:46 EDT
Volume:103.78M
Turnover:198.81M
Market Cap:9.26M
PE:-0.51
High:2.31
Open:2.02
Low:1.27
Close:1.44
Loading ...

Plus Therapeutics sees $15M in gross proceeds from private placement

TIPRANKS
·
05 Mar

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

THOMSON REUTERS
·
05 Mar

Plus Therapeutics granted orphan designation for lung cancer treatment

TIPRANKS
·
01 Mar

Plus Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview

Reuters
·
28 Feb

Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
27 Feb

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients With Leptomeningeal Metastases

THOMSON REUTERS
·
26 Feb

Plus Therapeutics appoints Russell Bradley as president, CNSide

TIPRANKS
·
24 Feb

Plus Therapeutics Announces Leadership Appointments for Its Cnside Diagnostics Subsidiary

THOMSON REUTERS
·
24 Feb

Plus Therapeutics Appoints DR. Michael Rosol as Chief Development Officer

THOMSON REUTERS
·
20 Feb

Plus Therapeutics secures $5.7M financing

TIPRANKS
·
18 Feb

Press Release: Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

Dow Jones
·
18 Feb

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

THOMSON REUTERS
·
18 Feb

Plus Therapeutics expands strategic agreement with Telix IsoTherapeutics

TIPRANKS
·
03 Dec 2024

Plus Therapeutics Expands Strategic Agreement With Telix Isotherapeutics Group for Rhenium-186 Radioisotope Supply

THOMSON REUTERS
·
03 Dec 2024

Plus Therapeutics Inc : Jonestrading Cuts Target Price to $10 From $32

THOMSON REUTERS
·
18 Nov 2024

Plus Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
15 Nov 2024